Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) EBIT (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed EBIT for 3 consecutive years, with -$33.8 million as the latest value for Q3 2025.

  • On a quarterly basis, EBIT rose 27.75% to -$33.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$154.0 million, a 57.83% increase, with the full-year FY2024 number at -$331.4 million, down 51.19% from a year prior.
  • EBIT was -$33.8 million for Q3 2025 at Inhibrx Biosciences, down from -$27.4 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$27.4 million in Q2 2025 to a low of -$160.9 million in Q2 2024.
  • A 3-year average of -$60.6 million and a median of -$46.3 million in 2023 define the central range for EBIT.
  • Peak YoY movement for EBIT: tumbled 289.22% in 2024, then skyrocketed 82.98% in 2025.
  • Inhibrx Biosciences' EBIT stood at -$83.8 million in 2023, then soared by 40.39% to -$49.9 million in 2024, then skyrocketed by 32.28% to -$33.8 million in 2025.
  • Per Business Quant, the three most recent readings for INBX's EBIT are -$33.8 million (Q3 2025), -$27.4 million (Q2 2025), and -$42.9 million (Q1 2025).